http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 06:31:24 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced it has entered binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.</p><p>CL-273 is an investigational pan-EGFR inhibitor designed using artificial intelligence for treating EGFR-mutant lung cancer. The drug targets resistant mutations that develop when using EGFR tyrosine kinase inhibitors, according to the press release statement.</p><p>The acquisition targets the EGFR-mutated lung cancer treatment market, estimated at $16.2 billion in 2026 by Future Market Insights. EGFR mutations are present in approximately 10-15% of non-small cell lung cancer cases in Western populations and up to 50% in http://www.streetinsider.com/Corporate+News/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html Mon, 02 Mar 2026 06:31:24 -0500 KAPA http://www.streetinsider.com/Mergers+and+Acquisitions/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced it has entered binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.</p><p>CL-273 is an investigational pan-EGFR inhibitor designed using artificial intelligence for treating EGFR-mutant lung cancer. The drug targets resistant mutations that develop when using EGFR tyrosine kinase inhibitors, according to the press release statement.</p><p>The acquisition targets the EGFR-mutated lung cancer treatment market, estimated at $16.2 billion in 2026 by Future Market Insights. EGFR mutations are present in approximately 10-15% of non-small cell lung cancer cases in Western populations and up to 50% in http://www.streetinsider.com/Mergers+and+Acquisitions/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html Mon, 02 Mar 2026 06:31:24 -0500 KAPA http://www.streetinsider.com/Hot+Corp.+News/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced it has entered binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.</p><p>CL-273 is an investigational pan-EGFR inhibitor designed using artificial intelligence for treating EGFR-mutant lung cancer. The drug targets resistant mutations that develop when using EGFR tyrosine kinase inhibitors, according to the press release statement.</p><p>The acquisition targets the EGFR-mutated lung cancer treatment market, estimated at $16.2 billion in 2026 by Future Market Insights. EGFR mutations are present in approximately 10-15% of non-small cell lung cancer cases in Western populations and up to 50% in http://www.streetinsider.com/Hot+Corp.+News/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html Mon, 02 Mar 2026 06:31:24 -0500 KAPA http://www.streetinsider.com/Hot+M+and+A/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced it has entered binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.</p><p>CL-273 is an investigational pan-EGFR inhibitor designed using artificial intelligence for treating EGFR-mutant lung cancer. The drug targets resistant mutations that develop when using EGFR tyrosine kinase inhibitors, according to the press release statement.</p><p>The acquisition targets the EGFR-mutated lung cancer treatment market, estimated at $16.2 billion in 2026 by Future Market Insights. EGFR mutations are present in approximately 10-15% of non-small cell lung cancer cases in Western populations and up to 50% in http://www.streetinsider.com/Hot+M+and+A/Kairos+Pharma+to+acquire+lung+cancer+drug+CL-273+from+Celyn+Therapeutics/26086458.html Mon, 02 Mar 2026 06:31:24 -0500 KAPA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Mar+02/26086466.html si-local-file:///var/storage/secattach/20260302/26086466.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Mar+02/26086466.html Mon, 02 Mar 2026 06:31:00 -0500 KAPA O.67432597 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Mar+02/26086466.html si-local-file:///var/storage/secattach/20260302/26086466.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kairos+Pharma%2C+LTD.+++++++For%3A+Mar+02/26086466.html Mon, 02 Mar 2026 06:31:00 -0500 KAPA O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html <p> <i>The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. </p><p> John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: “The signing of binding terms to acquire CL‑273 represents a pivotal step in building Kairos Pharma’s next generation of targeted therapies for EGFR‑mutant lung cancer. This http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html Mon, 02 Mar 2026 06:30:00 -0500 KAPA O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html <p> <i>The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. </p><p> John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: “The signing of binding terms to acquire CL‑273 represents a pivotal step in building Kairos Pharma’s next generation of targeted therapies for EGFR‑mutant lung cancer. This http://www.streetinsider.com/Press+Releases/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html Mon, 02 Mar 2026 06:30:00 -0500 KAPA O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html <p> <i>The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. </p><p> John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: “The signing of binding terms to acquire CL‑273 represents a pivotal step in building Kairos Pharma’s next generation of targeted therapies for EGFR‑mutant lung cancer. This http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html Mon, 02 Mar 2026 06:30:00 -0500 KAPA O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html <p> <i>The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. </p><p> John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: “The signing of binding terms to acquire CL‑273 represents a pivotal step in building Kairos Pharma’s next generation of targeted therapies for EGFR‑mutant lung cancer. This http://www.streetinsider.com/Business+Wire/Kairos+Pharma+Announces+Signing+of+Binding+Strategic+Asset+Acquisition+of+Exclusive+Worldwide+Rights+to+CL-273+From+OrbiMed+and+Torrey+Pines+Investment-Backed+Celyn+Therapeutics/26086407.html Mon, 02 Mar 2026 06:30:00 -0500 KAPA O.67432597 http://www.streetinsider.com/Corporate+News/Kairos+Pharma+signs+term+sheet+to+acquire+two+oncology+assets/26064211.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced it signed a term sheet to acquire two clinical-stage oncology assets from Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment.</p><p>The proposed acquisition would give Kairos worldwide rights to CL-273, a pre-IND pan-EGFR inhibitor, and CL-741, a Phase 1-ready c-MET kinase inhibitor. Both compounds target non-small cell lung cancer.</p><p>"We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs," said John Yu, Chief Executive Officer of Kairos Pharma.</p><p>CL-273 is designed to maintain http://www.streetinsider.com/Corporate+News/Kairos+Pharma+signs+term+sheet+to+acquire+two+oncology+assets/26064211.html Thu, 26 Feb 2026 07:02:18 -0500 KAPA http://www.streetinsider.com/Mergers+and+Acquisitions/Kairos+Pharma+signs+term+sheet+to+acquire+two+oncology+assets/26064211.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced it signed a term sheet to acquire two clinical-stage oncology assets from Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment.</p><p>The proposed acquisition would give Kairos worldwide rights to CL-273, a pre-IND pan-EGFR inhibitor, and CL-741, a Phase 1-ready c-MET kinase inhibitor. Both compounds target non-small cell lung cancer.</p><p>"We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs," said John Yu, Chief Executive Officer of Kairos Pharma.</p><p>CL-273 is designed to maintain http://www.streetinsider.com/Mergers+and+Acquisitions/Kairos+Pharma+signs+term+sheet+to+acquire+two+oncology+assets/26064211.html Thu, 26 Feb 2026 07:02:18 -0500 KAPA http://www.streetinsider.com/Hot+Corp.+News/Kairos+Pharma+signs+term+sheet+to+acquire+two+oncology+assets/26064211.html <p>Kairos Pharma, Ltd. (NYSE American: KAPA) announced it signed a term sheet to acquire two clinical-stage oncology assets from Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment.</p><p>The proposed acquisition would give Kairos worldwide rights to CL-273, a pre-IND pan-EGFR inhibitor, and CL-741, a Phase 1-ready c-MET kinase inhibitor. Both compounds target non-small cell lung cancer.</p><p>"We anticipate this acquisition will significantly expand our oncology pipeline with late-preclinical and Phase 1-ready assets in a multi-billion dollar market with substantial unmet medical needs," said John Yu, Chief Executive Officer of Kairos Pharma.</p><p>CL-273 is designed to maintain http://www.streetinsider.com/Hot+Corp.+News/Kairos+Pharma+signs+term+sheet+to+acquire+two+oncology+assets/26064211.html Thu, 26 Feb 2026 07:02:18 -0500 KAPA http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Press+Releases/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597 http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html <p> <i>Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market.</i> </p> <p> LOS ANGELES--(BUSINESS WIRE)-- <b>Kairos Pharma, Ltd. (NYSE American: KAPA),</b> a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small http://www.streetinsider.com/Business+Wire/Kairos+Pharma%2C+Ltd.+Announces+Signing+of+Term+Sheet+for+Strategic+Asset+Acquisition+of+Two+Clinical+Oncology+Assets+from+Celyn+Therapeutics/26064082.html Thu, 26 Feb 2026 07:00:00 -0500 A.19385386 A.60003641 KAPA O.00048410 O.19961569 O.67432597